Adamis Pharmaceuticals Corp

NASDAQ:ADMP  
0.20
-0.03 (-11.68%)
Products, Regulatory

Adamis Provides An Enrollment Update On The Phase 2/3 Study Of Tempol In COVID-19 Positive High-Risk Subjects

Published: 09/12/2022 21:34 GMT
Adamis Pharmaceuticals Corp (ADMP) - Adamis Provides an Enrollment Update on the Phase 2/3 Study of Tempol in Covid-19 Positive High-risk Subjects.
Adamis Pharmaceuticals Corp - Independent Data Monitoring Board to Review Interim Data From Approximately 200 Initial Subjects.
Adamis Pharmaceuticals Corp - Clinical Trial of Tempol Has Reached Initial Planned Enrollment of 248 Subjects.
Adamis Pharmaceuticals Corp - If Analysis of Interim Clinical Data Showed Significant Efficacy, Dsmb May Recommend Stopping Trial.
Adamis Pharmaceuticals Corp - If Interim Data Indicated No Efficacy on Primary Endpoint, Dsmb Would Likely Recommend Stopping Trial for Futility.